Overview

Notitia (“NO-TEE-SHA”) means “data” in Latin. We are a microbiome company that applies a data-driven approach to develop innovative products for the ecological restoration of a healthy gut microbiome. Our mission is to promote health by protecting and/or restoring the Foundation Guild™ of the gut microbiome. Our vision is to maximize everyone's healthspan by keeping their gut microbiome to the healthiest possible status for the longest possible time. The work of Dr. Liping Zhao, co-founder of Notitia, shows that a healthy gut microbiome is dominated by a specific group of beneficial bacteria named the "Foundation Guild." The Foundation Guild™ not only produces beneficial compounds essential to human health but also creates an environment that can suppress the overgrowing pathogens. Restoration and maintenance of the Foundation Guild™ are fundamental to improve health and wellness in patients with unmet medical needs and the generally healthy population. Notitia has developed a revolutionary Foundation Guild™ R&D platform which consists of three technologies: identification, isolation & preservation, and nutritional formulas to support the Foundation Guild™ bacteria. Notitia has created several products based on the Foundation Guild™ R&D platform for patients as well as for the generally healthy population. Foundation Guild™ Wellness Program: a monthly subscription service that provides: 1. Guild:Plus microbiome nutrition 2. Guild:Health data tracking portal 3. Guild:Quest microbiome test kit 4. Guild:Save bio-banking 5. Guild:Pro personalized family-based probiotics. Foundation Guild™ Clinical Program: 1. NBT-NM108, a botanical drug for promoting the Foundation Guild, currently available in a phase 2 trial for COVID-19 and expanded access programs. Additional trials for MS, DKD, Cancer, and Parkinson's will be available by Dec 2021. 2. NBT-BM306, a live biotherapeutic product for restoring the Foundation Guild. Phase 1 trial will be available by Dec 2021.